Vanda Pharmaceuticals scores second FDA approval in 2 months
- Washington Business Journal
- Feb 23
- 1 min read
Updated: Mar 24
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has landed another regulatory approval, this time for a schizophrenia and bipolar treatment - two months after securing a nod to take a motion sickness medication to market...
Read more at WBJ.
Comments